Düdingen, Switzerland / Munich, Germany – October 28, 2025 – athagroas is proud to announce the acquisition of confinis ag, a Switzerland-based tech enabled consulting firm specializing in regulatory affairs, quality assurance, and compliance solutions for MedTech and pharmaceutical clients across Europe and North America.
Founded in 2005 and headquartered in Düdingen, Switzerland, confinis has built a strong reputation for scientific depth and operational excellence. With long-standing, trust-based relationships across more than 100 active clients, and a comprehensive service portfolio spanning regulatory submissions, QMS implementation, clinical documentation, and post-market support, confinis represents a key addition to athagoras’ growing platform.
confinis will join athagoras’ Regulatory Affairs and Pharmacovigilance Division, a growing group of specialized firms, alongside CSO Pharma, S-Cubed, and DiaMed,to offer integrated services that span the full product lifecycle: from pre-market strategy and market clearance to post-market surveillance, real-world data, and health economics.
“With confinis, we welcome a deeply experienced team and a company whose expertise and entrepreneurial culture align perfectly with our ambition to build a science-driven, pan-European leader in Life Sciences services,” said Giuseppe Pileggi, CEO of athagoras.
“This step marks both a continuation and a new beginning,” said Dr. Andrea Biasiucci, CEO of confinis. “We’ve shaped confinis into a resilient, mission-focused, AI-native organization. Now, alongside our peers at athagoras we’re positioned to offer clients broader, deeper support, without compromising on the quality and independence they’ve come to expect.”
The acquisition enhances athagoras’ ability to provide a fully integrated regulatory and compliance ecosystem, advancing its long-term vision to become the partner of choice for Life Sciences companies navigating complex global regulatory environments.
